Poolbeg Pharma PLC Favourable Conclusion of Patent Opposition (0832O)
29 Septiembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 0832O
Poolbeg Pharma PLC
29 September 2023
Poolbeg Pharma plc
Positive Conclusion Reached in Immunomodulator I Patent
Opposition
Patent opposition hearing cancelled
29 September 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company targeting diseases with a high unmet medical need,
announces that further to its announcement on 19 September 2023 ,
the oral opposition hearing scheduled by the European Patent Office
('EPO') relating to the challenge to the Company's European patent
(Immunomodulator I), has been cancelled. This favourably concludes
this matter with the patent maintained as granted.
The Immunomodulator I European patent was opposed by a third
party in September 2021 and the opposition was subsequently
withdrawn in September 2023. Following the opposition withdrawal,
the EPO has now concluded that there is no need to proceed with the
scheduled hearing, concluding this matter.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, said: "I am delighted to share that the European Patent
Office has decided against proceeding with the scheduled hearing,
following the withdrawal of the patent opposition by a third party.
We have always maintained confidence in the strength and validity
of our patents and we are pleased to bring this matter to a close
and look forward to continuing to strengthen our IP protection of
this exciting molecule."
Footnote:
Immunomodulator I: Use of p38 MAPK inhibitors for the treatment
of severe influenza
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Hana Malik, Vici Rabbetts poolbeg@optimumcomms.com
About Poolbeg Pharma
Poolbeg Pharma specialises in the development of innovative
medicines to address the unmet need in infectious and other
prevalent diseases. Poolbeg Pharma has a disciplined portfolio
approach to mitigate risk, accelerate drug development, and enhance
investor returns. The Company simultaneously advances multiple
programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline.
Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to
faster development and greater commercial appeal.
The Company is targeting the growing infectious disease market.
In the wake of the COVID-19 pandemic, infectious disease has become
one of the fastest growing pharma markets and is expected to exceed
$250bn by 2025. Through opportunistic identification of assets
which complement Poolbeg Pharma's existing pipeline, the Company is
progressing programmes in oncology and metabolic syndromes; adding
disease areas with significant addressable markets.
With its initial assets from hVIVO plc , an industry leading
infectious disease and human challenge trials business, Poolbeg
Pharma has access to knowledge, experience, and clinical data from
over 20 years of human challenge trials. The Company is using these
insights to acquire new assets as well as reposition clinical stage
products, reducing spend and risk. Amongst its portfolio of
exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction
in p38 MAP kinase driven cytokines in a clinical setting; a
first-in-class, intranasally administered RNA-based immunotherapy
for respiratory virus infections (POLB 002); and a vaccine
candidate for Melioidosis (POLB 003). The Company is progressing
two A rtificial I ntelligence (AI) P rogrammes to add promising new
assets to its pipeline as well as developing an Oral Vaccine
Programme and an Oral Delivery Programme focussing on metabolic
syndrome related diseases.
For more information, please go to www.poolbegpharma.com or
follow us on Twitter and LinkedIn @PoolbegPharma.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCLPMMTMTJTTRJ
(END) Dow Jones Newswires
September 29, 2023 02:00 ET (06:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De May 2023 a May 2024